

Brian J Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/27043/publications.pdf>

Version: 2024-02-01

93
papers

6,857
citations

126907

33
h-index

60623

81
g-index

93
all docs

93
docs citations

93
times ranked

8740
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. <i>Biological Psychiatry</i> , 2011, 70, 663-671.	1.3	1,448
2	Psychiatric Comorbidities and Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 383-402.	4.3	867
3	Meta-Analysis of Oxidative Stress in Schizophrenia. <i>Biological Psychiatry</i> , 2013, 74, 400-409.	1.3	408
4	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. <i>Molecular Neurobiology</i> , 2018, 55, 4195-4206.	4.0	279
5	Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients. <i>Biological Psychiatry</i> , 2015, 78, 28-37.	1.3	272
6	Inflammation and Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 1174-1179.	4.3	266
7	Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. <i>Schizophrenia Bulletin</i> , 2018, 44, 75-83.	4.3	262
8	Mortality and Medical Comorbidity Among Patients With Serious Mental Illness. <i>Psychiatric Services</i> , 2006, 57, 1482-1487.	2.0	235
9	C-Reactive Protein Levels in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 7, 223-230.	1.4	202
10	Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects. <i>Biological Psychiatry</i> , 2013, 73, 993-999.	1.3	180
11	Meta-analysis of Paternal Age and Schizophrenia Risk in Male Versus Female Offspring. <i>Schizophrenia Bulletin</i> , 2011, 37, 1039-1047.	4.3	167
12	Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions. <i>Neuropsychopharmacology</i> , 2017, 42, 299-317.	5.4	132
13	How connected are people with schizophrenia? Cell phone, computer, email, and social media use. <i>Psychiatry Research</i> , 2015, 225, 458-463.	3.3	103
14	Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 92-100.	4.8	101
15	A systematic, quantitative review of blood autoantibodies in schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 245-251.	2.0	93
16	TNF- α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 199, 281-284.	2.0	93
17	Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis. <i>Schizophrenia Research</i> , 2017, 179, 57-63.	2.0	85
18	Parental history of Type 2 diabetes in patients with nonaffective psychosis. <i>Schizophrenia Research</i> , 2008, 98, 302-306.	2.0	74

#	ARTICLE	IF	CITATIONS
19	Is Abnormal Glucose Tolerance in Antipsychotic-Naive Patients With Nonaffective Psychosis Confounded by Poor Health Habits?. <i>Schizophrenia Bulletin</i> , 2012, 38, 280-284.	4.3	69
20	Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue. <i>Cancer</i> , 2015, 121, 2129-2136.	4.1	68
21	An Open-Label, Pilot Trial of Adjunctive Tocilizumab in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 275-276.	2.2	65
22	Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis. <i>Schizophrenia Research</i> , 2016, 174, 156-160.	2.0	64
23	Meta-analysis of total and differential white blood cell counts in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 18-26.	4.5	62
24	Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 63, 144-154.	2.7	58
25	Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 989-998.	4.3	53
26	A Prevalence Study of Urinary Tract Infections in Acute Relapse of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 271-277.	2.2	50
27	Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. <i>Brain, Behavior, and Immunity</i> , 2013, 31, 82-89.	4.1	48
28	Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. <i>Psychoneuroendocrinology</i> , 2021, 127, 105200.	2.7	43
29	Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. <i>Schizophrenia Research</i> , 2020, 226, 5-12.	2.0	40
30	Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 8, 73-79.	1.4	39
31	A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis. <i>Journal of Psychiatric Practice</i> , 2008, 14, 289-300.	0.7	38
32	Beyond Urinary Tract Infections (UTIs) and Delirium. <i>Journal of Psychiatric Practice</i> , 2015, 21, 402-411.	0.7	38
33	Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 756-770.	4.1	38
34	The Antipsychotic Effects of ECT. <i>Journal of ECT</i> , 2014, 30, 125-131.	0.6	37
35	Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology. <i>Biomarkers in Neuropsychiatry</i> , 2019, 1, 100006.	1.0	37
36	Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. <i>Psychiatry Research</i> , 2018, 260, 307-312.	3.3	36

#	ARTICLE	IF	CITATIONS
37	The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2016, 39, 187-198.	1.3	32
38	Meta-analysis of blood cortisol levels in individuals with first-episode psychosis. <i>Psychoneuroendocrinology</i> , 2019, 104, 269-275.	2.7	32
39	Insomnia and suicidal ideation in nonaffective psychosis. <i>Sleep</i> , 2019, 42, .	1.1	32
40	Meta-Analysis of Cytokine and Chemokine Genes in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2018, 12, 121-129B.	1.4	32
41	Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder. <i>Focus (American Tj ETQq1 1 0.784314 rgBT /Overlock 10</i>	0.8	31
42	Urinary Tract Infections in Acute Psychosis. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 379-385.	2.2	31
43	Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. <i>Brain, Behavior, and Immunity</i> , 2015, 45, 28-35.	4.1	30
44	Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2015, 169, 30-35.	2.0	27
45	Electronic cigarette use in patients with schizophrenia: Prevalence and attitudes. <i>Annals of Clinical Psychiatry</i> , 2017, 29, 4-10.	0.6	27
46	Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 45-53.	2.0	25
47	Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2018, 195, 275-282.	2.0	24
48	Longitudinal study of inflammatory markers and psychopathology in schizophrenia. <i>Schizophrenia Research</i> , 2020, 224, 58-66.	2.0	22
49	Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine. <i>Schizophrenia Research</i> , 2019, 206, 21-26.	2.0	21
50	Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis. <i>General Hospital Psychiatry</i> , 2019, 61, 41-46.	2.4	20
51	Psychosis as an adverse effect of antibiotics. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 9, 100148.	2.5	19
52	Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 609-622.	3.2	19
53	Insomnia, suicidal ideation, and psychopathology in Chinese patients with chronic schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110202.	4.8	18
54	Personalized medicine for schizophrenia. <i>NPJ Schizophrenia</i> , 2017, 3, 2.	3.6	17

#	ARTICLE	IF	CITATIONS
55	Monoclonal antibody immunotherapy in psychiatric disorders. <i>Lancet Psychiatry</i> , 2017, 4, 13-15.	7.4	16
56	Urinary tract infections in children and adolescents with acute psychosis. <i>Schizophrenia Research</i> , 2017, 183, 36-40.	2.0	16
57	Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2019, 209, 193-197.	2.0	16
58	Advanced Paternal Age, Mortality, and Suicide in the General Population. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 404-411.	1.0	15
59	Psychosis as an adverse effect of monoclonal antibody immunotherapy. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 646-649.	4.1	13
60	Meta-analysis of comorbid diabetes and family history of diabetes in non-affective psychosis. <i>Schizophrenia Research</i> , 2020, 216, 41-47.	2.0	13
61	Recurrent urinary tract infections in acute psychosis. <i>Schizophrenia Research</i> , 2015, 164, 275-276.	2.0	12
62	Parental type 2 diabetes in patients with non-affective psychosis. <i>Schizophrenia Research</i> , 2016, 175, 223-225.	2.0	12
63	Insomnia, Suicidal Ideation, and Suicide Attempts in the Clinical Antipsychotic Trials of Intervention Effectiveness. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	12
64	Monitoring for myocarditis during treatment initiation with clozapine. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 194-200.	4.5	11
65	US Medical Licensing Exam Scores and Performance on the Psychiatry Resident In-Training Examination. <i>Academic Psychiatry</i> , 2014, 38, 627-631.	0.9	10
66	Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 517-522.	2.6	10
67	Paternal age and mortality in nonaffective psychosis. <i>Schizophrenia Research</i> , 2010, 121, 218-226.	2.0	8
68	Differential white blood cell counts may predict urinary tract infection in acute non-affective psychosis. <i>Schizophrenia Research</i> , 2013, 147, 400-401.	2.0	8
69	Is Relapse in Schizophrenia an Immune-Mediated Effect?. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 115-123.	0.8	6
70	The pupillary light reflex as a point-of-care test for suicide risk: Preliminary results. <i>Psychiatry Research</i> , 2021, 295, 113582.	3.3	6
71	The interaction of lipids and inflammatory markers predict negative symptom severity in patients with schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 50.	3.6	6
72	Development of Autonomic Nervous System Assays as Point-of-Care Tests to Supplement Clinical Judgment in Risk Assessment for Suicidal Behavior: A Review. <i>Current Psychiatry Reports</i> , 2022, 24, 11-21.	4.5	6

#	ARTICLE	IF	CITATIONS
73	O10.5. META-ANALYSIS OF CYTOKINE LEVELS AND PSYCHOPATHOLOGY IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S191-S192.	4.3	5
74	Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia Research, 2019, 208, 44-48.	2.0	5
75	Total and Differential White Blood Cell Counts, Cocaine, and Marijuana Use in Patients With Schizophrenia. Journal of Nervous and Mental Disease, 2019, 207, 633-636.	1.0	5
76	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive Psychiatry, 2020, 102, 152195.	3.1	5
77	Pupillary light reflex markers of suicide risk in a trans-diagnostic sample. Schizophrenia Research, 2021, 235, 1-2.	2.0	5
78	Schizophrenia Research. Psychiatric Clinics of North America, 2015, 38, 373-377.	1.3	4
79	Acutely ill psychiatric inpatients and antimicrobial exposure. , 2020, 32, 229-238.		4
80	Epigenetics and first-episode psychosis: A systematic review. Psychiatry Research, 2022, 307, 114325.	3.3	4
81	Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia. Schizophrenia Research, 2014, 158, 268-269.	2.0	3
82	Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Psychiatry Research, 2021, 305, 114195.	3.3	3
83	Recurrent urinary tract infections in children and adolescents with acute psychosis. Schizophrenia Research, 2017, 184, 103-104.	2.0	2
84	Medication management of antipsychotic treatment in schizophreniaâ€”A narrative review. Human Psychopharmacology, 2021, 36, e2765.	1.5	2
85	Insomnia and triglycerides in schizophrenia. Schizophrenia Research, 2022, 239, 42-43.	2.0	2
86	Recurrent urinary tract infections in psychotic mood disorders. Schizophrenia Research, 2017, 184, 137-138.	2.0	1
87	Reply to the Letter to the Editor: Reduced neuropsychiatric events as â€œbeneficial reactionsâ€ to drugs: Seek associations with caution. Brain, Behavior, and Immunity, 2020, 84, 277.	4.1	1
88	Screening for plagiarism in psychiatric research: Similarity scores are not all the same. Journal of Psychiatric Research, 2020, 131, 31-32.	3.1	1
89	A dose reduction/discontinuation strategy improves long-term recovery in people with remitted first-episode psychosis compared to maintenance therapy. Evidence-Based Mental Health, 2014, 17, 10-10.	4.5	0
90	F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE. Schizophrenia Bulletin, 2018, 44, S242-S243.	4.3	0

#	ARTICLE	IF	CITATIONS
91	2329 Associations between inflammatory markers and negative symptoms in individuals with schizophrenia: Converging evidence. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 4-4.	0.6	0
92	Rheumatoid Arthritis Drugs for Schizophrenia?. <i>Psychiatric Annals</i> , 2018, 48, 232-236.	0.1	0
93	Urinary tract infection, inflammation, and cognition in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i>Annals of Clinical Psychiatry</i> , 2019, 31, 242-248.	0.6	0